Heart failure diagnosis marker and application thereof

By discovering the diagnostic value of C1QTNF9, CCR1, CD163 and P2RY13 genes and the target binding force of Xiangqinglan total flavonoid extract, the problem of diagnosis and treatment of ischemic heart failure was solved, and the accurate diagnosis of ischemic heart failure was achieved and Potential treatment options.

CN119144713APending Publication Date: 2024-12-17XINJIANG INST OF MATERIA MEDICA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411288345.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-12-17

AI Technical Summary

Technical Problem

The prior art lacks effective gene markers for the early diagnosis and treatment of ischemic heart failure, resulting in patients not being able to obtain effective intervention in a timely manner, affecting prognosis and reducing mortality.

Method used

C1QTNF9, CCR1, CD163 and P2RY13 genes were found to have significant diagnostic value in ischemic heart failure, and combined with Xiangqinglan Total Flavonoid Extract, it is used to prepare reagents and drugs for the diagnosis and treatment of heart failure, and by detecting these genes Expression levels and protein target binding to extracts have been developed to prevent ischemic heart failure.

Benefits of technology

By detecting the expression levels of C1QTNF9, CCR1, CD163 and P2RY13, an accurate diagnosis of ischemic heart failure was achieved. In addition, the strong binding force of Xiangqinglan total flavonoid extract to the proteins encoded by these genes is expected to be developed to prevent ischemic Drugs for sexual heart failure improve diagnostic efficiency and therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119144713A_ABST
    Figure CN119144713A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of gene diagnosis and biological medicine, and particularly relates to a heart failure diagnosis marker and application thereof. According to the present invention, the expression levels of C1QTNF9, CCR1, CD163 and P2RY13 in ischemic heart failure patients and healthy individuals are significantly different, and the research results show that the areas (AUC) of the four genes under the receiver operation characteristic curve (ROC) are respectively 0.967, 0.983, 1.000 and 1.000, such that the C1QTNF9 gene, the CCR1 gene, the CD163 gene and the P2RY13 gene have significant diagnosis values in the prediction of ischemic heart failure.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of gene diagnosis and biomedicine technology, and specifically relates to a heart failure diagnostic marker and application thereof. Background Art

[0002] Heart failure (HF) is a clinical syndrome caused by multiple etiologies, which leads to changes in myocardial structure and function, resulting in impaired ventricular filling and ejection function. This condition not only poses a serious threat to the patient's life, but also brings a significant economic burden to the patient's family and society.

[0003] Ischemic heart failure is a special form of heart failure, mainly caused by coronary artery obstruction caused by coronary atherosclerotic plaques. This leads to prolonged myocardial ischemia and hypoxia, followed by conditions such as myocardial cell death and myocardial fibrosis, ultimately leading to decreased cardiac function and the onset of heart failure. This condition usually occurs in the late stages of coronary artery disease and is prone to symptoms such as arrhythmias, leading to the death of patients in a relatively short period of time.

[0004] Traditional treatments for ischemic heart failure usually include vasodilation, increased blood oxygen content, and antithrombotic therapy to help patients with medication. However, these measures do not improve the underlying condition of increased oxygen demand in patients. Therefore, although patients receiving conventional treatment may survive if they receive timely rescue, their hearts may also suffer serious damage, which is not conducive to their future quality of life. Therefore, early diagnosis and timely and effective intervention are crucial to improving the prognosis of patients with ischemic heart failure and reducing mortality.

[0005] Genetic markers refer to disease-related gene mutations and expressions. With the widespread application of high-throughput technology, genetic marker research has become an increasingly important means of disease diagnosis and treatment. For example, genetic markers have been widely used in the diagnosis of diseases such as lung cancer, breast cancer, liver cancer, and colorectal cancer. However, there is currently a lack of effective genetic markers related to ischemic heart failure in this field. Summary of the invention

[0006] The purpose of the present invention is to provide a diagnostic marker for heart failure and its application. The present invention finds that C1QTNF9, CCR1, CD163 and P2RY13 have significant diagnostic value in ischemic heart failure.

[0007] The present invention provides the use of characteristic genes as targets in the preparation of reagents for diagnosing heart failure, wherein the characteristic genes include one or more of C1QTNF9, CCR1, CD163 and P2RY13.

[0008] The present invention also provides the use of a reagent for detecting the expression level of characteristic genes in preparing a reagent for diagnosing heart failure, wherein the characteristic genes include one or more of C1QTNF9, CCR1, CD163 and P2RY13.

[0009] Preferably, the expression of C1QTNF9 is upregulated, the expression of CCR1 is downregulated, the expression of CD163 is downregulated, and the expression of P2RY13 is upregulated.

[0010] The present invention also provides the use of characteristic genes combined with the total flavonoids extract of Herba Cinerariae in preparing a drug for diagnosing and / or treating heart failure, wherein the characteristic genes include one or more of C1QTNF9, CCR1, CD163 and P2RY13.

[0011] Preferably, the heart failure includes ischemic heart failure.

[0012] The present invention also provides a kit, which includes a reagent for detecting the expression level of characteristic genes, and the characteristic genes include one or more of C1QTNF9, CCR1, CD163 and P2RY13.

[0013] The present invention also provides a method for detecting heart failure for non-disease diagnosis purposes, comprising the following steps: detecting the expression levels of C1QTNF9, CCR1, CD163 and P2RY13 in a sample to be tested, and judging whether the sample to be tested is a heart failure sample based on the expression levels of C1QTNF9, CCR1, CD163 and P2RY13:

[0014] When one or more of the following four items are met, the sample to be tested is a heart failure sample;

[0015] 1) the expression of C1QTNF9 is upregulated;

[0016] 2) down-regulation of the expression of CCR1;

[0017] 3) the expression of CD163 is downregulated;

[0018] 4) the expression of P2RY13 is upregulated;

[0019] Except for satisfying one or more of the above four items, the sample to be tested is a non-heart failure sample.

[0020] Preferably, the detecting the expression levels of C1QTNF9, CCR1, CD163 and P2RY13 in the test sample comprises: detecting the relative expression levels of C1QTNF9, CCR1, CD163 and P2RY13 in the test sample relative to the healthy sample.

[0021] Preferably, the heart failure includes ischemic heart failure.

[0022] The present invention also provides a diagnostic marker for heart failure, comprising two or more of C1QTNF9, CCR1, CD163 and P2RY13 genes.

[0023] Beneficial effects:

[0024] The present invention provides an application of a characteristic gene in the preparation of a reagent for diagnosing heart failure, wherein the characteristic gene includes one or more of C1QTNF9, CCR1, CD163 and P2RY13. The present invention finds that the expression levels of C1QTNF9, CCR1, CD163 and P2RY13 in patients with ischemic heart failure and healthy individuals are significantly different, and through research, it is found that the areas under the receiver operating characteristic curve (ROC) of C1QTNF9, CCR1, CD163 and P2RY13 are 0.967, 0.983, 1.000 and 1.000, respectively. It can be seen that the C1QTNF9, CCR1, CD163 and P2RY13 genes have significant diagnostic value in predicting ischemic heart failure. At the same time, the present invention also found that the protein molecules encoded by the C1QTNF9, CCR1, CD163 and P2RY13 genes have a strong target binding ability with the active ingredients in the total flavonoids extract (TFDM) of Fragrant Blue that has pharmacological protective effects on myocardial ischemia-reperfusion injury and cerebral ischemia-reperfusion injury, and is expected to be further developed into a drug for preventing ischemic heart failure. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.

[0026] Figure 1 The volcano plot is a diagram of differentially expressed genes between ischemic heart failure patients and controls identified in Example 1;

[0027] Figure 2 is a heat map of differentially expressed genes identified between ischemic heart failure patients and controls in Example 1;

[0028] Figure 3 The KEGG pathway analysis results of the function and pathway enrichment analysis in Example 1;

[0029] Figures 4-5 GO analysis results of function and pathway enrichment analysis in Example 1;

[0030] Figures 6 to 10 This is a graph showing the results of weighted gene co-expression network analysis in Example 1;

[0031] Figures 11 to 15 The result graph of selecting characteristic genes by LASSO and random forest algorithm in Example 1;

[0032] Figures 16 to 23 The expression levels and AUC results of C1QTNF9, CCR1, CD163 and P2RY13 genes in the prediction of ischemic heart failure in Example 1 are shown;

[0033] Figures 24 to 27 The figure is the result of gene set enrichment analysis of C1QTNF9, CCR1, CD163 and P2RY13 genes in Example 1;

[0034] Figures 28 to 31 This is the molecular docking result diagram of the active ingredients in TFDM in Example 1 with C1QTNF9, CCR1, CD163 and P2RY13. DETAILED DESCRIPTION

[0035] The present invention provides an application of characteristic genes as targets in the preparation of reagents for diagnosing heart failure, wherein the characteristic genes include one or more of C1QTNF9, CCR1, CD163 and P2RY13. The accession numbers of C1QTNF9, CCR1, CD163 and P2RY13 in the NCBI database are Gene ID: 239126, Gene ID: 1230, Gene: 9332 and Gene ID: 53829, respectively.

[0036] The present invention also provides the use of a reagent for detecting the expression level of a characteristic gene in the preparation of a reagent for diagnosing heart failure, wherein the characteristic gene includes one or more of C1QTNF9, CCR1, CD163 and P2RY13. The present invention finds that, compared with healthy individuals, in ischemic heart failure, the expression of C1QTNF9 is upregulated, the expression of CCR1 is downregulated, the expression of CD163 is downregulated, and the expression of P2RY13 is upregulated, and the expression levels are significantly different; at the same time, the present invention finds that the areas under the receiver operating characteristic curves (ROC) of C1QTNF9, CCR1, CD163 and P2RY13 are 0.967, 0.983, 1.000 and 1.000, respectively, that is, C1QTNF9, CCR1, CD163 and P2RY13 genes have significant diagnostic value in predicting ischemic heart failure.

[0037] The present invention also provides the use of characteristic genes combined with the total flavonoids extract of Herba Lysimachiae in the preparation of a drug for diagnosing and / or treating heart failure, wherein the characteristic genes include one or more of C1QTNF9, CCR1, CD163 and P2RY13. The present invention finds that the protein molecules encoded by the C1QTNF9, CCR1, CD163 and P2RY13 genes have a strong target binding ability with the effective components in the total flavonoids extract of Herba Lysimachiae (TFDM) having a pharmacological protective effect on myocardial ischemia-reperfusion injury and cerebral ischemia-reperfusion injury, and can be subsequently used to develop drugs for preventing and treating ischemic heart failure.

[0038] The heart failure described in the present invention preferably includes ischemic heart failure.

[0039] The present invention also provides a kit, the kit comprising a reagent for detecting the expression level of the characteristic gene, the characteristic gene comprising one or more of C1QTNF9, CCR1, CD163 and P2RY13. The present invention does not specifically limit the type of the reagent, and the conventional reagents for detecting the gene expression level in the art all fall within the protection scope of the reagent of the present invention.

[0040] The present invention also provides a method for detecting heart failure for non-disease diagnosis purposes, comprising the following steps: detecting the expression levels of C1QTNF9, CCR1, CD163 and P2RY13 in a sample to be tested, and judging whether the sample to be tested is a heart failure sample based on the expression levels of C1QTNF9, CCR1, CD163 and P2RY13:

[0041] When one or more of the following four items are met, the sample to be tested is a heart failure sample;

[0042] 1) the expression of C1QTNF9 is upregulated;

[0043] 2) down-regulation of the expression of CCR1;

[0044] 3) the expression of CD163 is downregulated;

[0045] 4) the expression of P2RY13 is upregulated;

[0046] Except for satisfying one or more of the above four items, the sample to be tested is a non-heart failure sample.

[0047] In the present invention, the detection of the expression levels of C1QTNF9, CCR1, CD163 and P2RY13 in the sample to be tested includes: detecting the relative expression levels of C1QTNF9, CCR1, CD163 and P2RY13 in the sample to be tested relative to the healthy sample. The heart failure described in the present invention includes ischemic heart failure.

[0048] The present invention also provides a diagnostic marker for heart failure, comprising two or more of C1QTNF9, CCR1, CD163 and P2RY13 genes.

[0049] In order to further illustrate the present invention, the technical solution provided by the present invention is described in detail below in conjunction with the accompanying drawings and embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0050] Example 1

[0051] Use of C1QTNF9, CCR1, CD163 and P2RY13 genes in preparing a reagent for diagnosing ischemic heart failure, the steps are as follows:

[0052] 1. Materials and methods:

[0053] Data source: This example downloaded a data set from the Gene Expression Omnibus (GEO) database (platform: GPL6244 [HuGene-1_0-st] Affymetrix Human Gene 1.0STArray [transcription gene version]). As a training set, it included 17 research subjects, including 12 patients with ischemic heart failure and 5 normal controls.

[0054] Identification of differentially expressed genes (DEGs): In this example, the R package limma was used to analyze the differentially expressed genes (DEGs) between the ischemic heart failure cohort and the control group, with criteria of p < 0.05 and fold change (log(FC)|>1). A volcano plot was generated to display these DEGs, while a heat map was used to illustrate the top 50 upregulated DEGs and the top 50 downregulated DEGs.

[0055] Functional and pathway enrichment analysis: This example uses the clusterProfiler package of R software, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) to perform functional enrichment analysis on differentially expressed genes (DEGs). As part of the GO analysis, this example identifies three categories: biological process (BP), cellular component (CC), and molecular function (MF), which helps to explore the biological processes associated with these DEGs. KEGG analysis was used to study potential signaling pathways.

[0056] Weighted gene co-expression network analysis: Based on the scale-free topological criterion, this embodiment uses weighted gene co-expression network analysis (WGCNA) to construct the co-expression network of the queue. The soft threshold power and adjacency matrix are calculated using the pickSoftThreshold function of the WGCNA software package. Subsequently, the adjacency matrix is ​​converted to a topological overlap matrix (TOM), and the corresponding differences of the hierarchical clustering analysis are calculated. Dynamic tree cutting is applied with a minimum module size of 50 to identify co-expressed gene modules. Then this embodiment measures the association between gene modules and ischemic heart failure by gene significance (GS) values ​​and module membership (MM) values, and finally identifies key modules.

[0057] Characteristic gene identification: This example identifies candidate hub genes by intersecting differentially expressed genes (DEGs) with key module genes. Subsequently, this example uses two machine learning algorithms, least absolute shrinkage and selection operator (LASSO) and random forest, to screen hub genes.

[0058] LASSO analysis was performed using the glmnet package with a penalty parameter and 10-fold cross validation, which is superior to regression analysis methods in evaluating high-dimensional data. In addition, this embodiment applied the R package "randomForest" to classify the DEGs of hub genes. The random forest model determines the optimal number of variables by calculating the average error rate of candidate hub genes. This embodiment then calculated the error rate of 1 to 500 trees and determined the number of optimal trees based on the lowest error rate. After establishing these parameters, a random forest tree model was constructed. Finally, each candidate hub gene was scored according to feature importance, and genes with importance values ​​greater than 0.25 were selected.

[0059] The genes that were intersected by these two machine learning algorithms were considered as the signature genes of patients with ischemic heart failure. The area under the receiver operating characteristic curve (ROCs) (AUC) was used to evaluate the diagnostic efficiency of these signature genes, and an AUC greater than 0.7 indicated good diagnostic performance.

[0060] Gene set enrichment analysis (GSEA): In order to determine the association between characteristic genes and signaling pathways, this example divided ischemic heart failure into different subgroups according to the median value of hub gene expression, and performed gene set enrichment analysis on the subgroups with adjusted p<0.05.

[0061] Molecular docking: In this example, molecular docking analysis was performed on the active compound components in the total flavonoids of fennel (TFDM), targeting CTRP9, CCR1, CD163 and P2Y13 proteins. Using "fennel" as a keyword, the chemical components of fennel were collected through literature search, BATMAN-TCM database and ChemSrc database (https: / / www.chemsrc.com / ). Potential active ingredients were screened based on pharmacokinetic parameters in the SwissADME (http: / / www.swissadme.ch / ) database. The screening criteria were as follows: (1) gastrointestinal absorption (GI absorption / GI absorption) in pharmacokinetics was defined as "high" as a condition for the chemical component; (2) bioavailability score ≥ 0.5; (3) at least two drug (drug similarity) rules were "yes"; (4) flavonoid active ingredients were screened.

[0062] The three-dimensional structural information of related proteins was obtained from the RCSB protein database (https: / / www.rcsb.org / ). Before molecular docking, the crystallographic solvent molecules and non-covalent ligands were removed using Discovery Studio software in this example, and hydrogen atoms were added and electrons were supplemented to the protein structure using AutoDockVina software.

[0063] The three-dimensional structures of the compounds were derived from the PubChem database (https: / / pubchem.ncbi.nlm.nih.gov) and were similarly processed using the AutoDockVina software, including hydrogen atom addition, electron supplementation, and the addition of rotatable and torsion bonds to ensure flexibility and accuracy during docking.

[0064] In the molecular docking program, the protein structure was set as a rigid body and the docking algorithm was executed to identify and record the top three conformations with the lowest binding energy for each protein. These conformations allowed us to assess the binding affinity of the compounds to their protein targets. Subsequently, the optimal molecular docking results were visualized using Pymol software.

[0065] In order to further study the interaction details between active compound molecules and CTRP9, CCR1, CD163 and P2Y13 target proteins, we used Discovery Studio software to perform detailed analysis of the molecular docking structure. This includes identifying and evaluating potential hydrogen bonds, hydrophobic interactions, van der Waals forces and other non-covalent interactions, thus providing key information for understanding the biological activity of the compound and its potential drug action mechanism.

[0066] 2. Statistical Analysis

[0067] All statistical analyses in this example were performed using R software (version 4.1.2). p<0.05 was considered statistically significant, and all p values ​​were two-sided.

[0068] 3. Results and Analysis

[0069] Identification of differentially expressed genes between ischemic heart failure patients and controls: The differentially expressed genes (DEGs) between ischemic heart failure patients and normal controls were analyzed using the "limma" software package. A total of 259 DEGs were identified, including 127 up-regulated and 132 down-regulated genes ( Figure 1 ). The top 50 up-regulated and top 50 down-regulated DEGs between the ischemic heart failure group and the healthy cohort were displayed using a heat map ( Figure 2 ).

[0070] Functional and pathway enrichment analysis: KEGG analysis revealed the most enriched pathways, including those mainly related to inflammatory response, muscular system processes, regulation of MAPK cascades, vascular development, regulation of cell activation, positive regulation of cell migration, and negative regulation of cell population proliferation ( Figure 3 ). GO analysis showed that the top three tissue specificities were heart, skeletal muscle, and smooth muscle. In terms of cell specificity, it involved cardiac stromal cells, cardiac myocytes, DRG cells, U87 cells, liposarcoma cells, etc. ( Figure 4 Potentially implicated diseases include myocardial ischemia, lupus nephritis, gestational diabetes, muscular dystrophy, and inflammation ( Figure 5 ).

[0071] Weighted gene co-expression network analysis: The WGCNA package was used in R software to analyze the ischemic heart failure patients and healthy subjects, and a scale-free co-expression network was established. The soft threshold power was determined to be 10 and the scale-free index was 0.85, indicating good average connectivity ( Figures 6-7 ). Figure 8 Finally, the data were integrated into 8 modules ( Fig. 9 ). The correlation between each module and patients with ischemic heart failure was calculated. The results showed that the MEturquoise module was significantly correlated with ischemic heart failure (correlation coefficient = -0.79, p < 0.0002). This module contains 595 genes and is considered to be a key module associated with patients with ischemic heart failure. Fig.10 The overlap between DEGs and genes within the MEturquoise module is shown.

[0072] Selection of characteristic genes by LASSO and random forest algorithms: Two machine learning algorithms were applied to select characteristic genes from candidate key genes of patients with ischemic heart failure. LASSO analysis identified 9 characteristic genes ( Figures 11-12 ), while random forest analysis identified 50 signature genes with a relative importance greater than 0.25 ( Figures 13-14 Through the interaction of these two algorithms, a set of four signature genes, namely C1QTNF9, CCR1, CD163, and P2RY13, were finally identified ( Fig.15 ).

[0073] Diagnostic utility of signature genes in the prediction of ischemic heart failure: The expression levels of the selected signature genes in patients with ischemic heart failure were significantly different from those in healthy individuals, suggesting that these genes may play a potential role in ischemic heart failure ( Figures 16 to 19 In addition, the area under the receiver operating characteristic curve (ROC) of these signature genes was calculated, and the AUC of C1QTNF9 was 0.967, the AUC of CCR1 was 0.983, the AUC of CD163 was 1.000, and the AUC of P2RY13 was 1.000 ( Figures 20-23 ). The results showed that the selected signature genes had significant diagnostic efficiency in predicting ischemic heart failure.

[0074] GSEA analysis: Through gene set enrichment analysis (GSEA), this example evaluated the signaling pathways associated with the characteristic genes. Figures 24 to 27 The top 10 up- and down-regulated signaling pathways are shown.

[0075] in Fig.24 The results showed that C1QTNF9 was significantly associated with the following pathways: vascular endothelial growth factor (VEGF) signaling pathway, valine, leucine and isoleucine degradation, ribosome, pyruvate metabolism, propionate metabolism, prion disease, peroxisome, NOD-like receptor (NLR) signaling pathway, leishmaniasis infection, intestinal immune network for intestinal IgA production, chondroitin sulfate glycosaminoglycan biosynthesis, fatty acid metabolism, cytokine-cytokine receptor interaction, complement and coagulation cascade, citric acid cycle (TCA cycle), butyrate metabolism, bladder cancer, β-alanine metabolism, aminoacyl-tRNA biosynthesis, ATP binding cassette (ABC) transporter. These associations suggest that C1QTNF9 may play a role in a variety of biological processes and disease states.

[0076] Fig.25The results showed that the expression of CCR1 was associated with the following signaling pathways: vascular endothelial growth factor (VEGF) signaling pathway, Toll-like receptor (TLR) signaling pathway, taste transduction, pyruvate metabolism, primary bile acid biosynthesis, peroxisomes, pathogenic Escherichia coli infection, olfactory transduction, leukocyte transendothelial migration, Huntington's disease, glycerate and dicarboxylic acid metabolism, chondroitin sulfate glycosaminoglycan biosynthesis, gap junctions, Fcγ-mediated phagocytosis, FcεRI signaling pathway, fatty acid metabolism, drug metabolism: cytochrome P450, citric acid cycle (TCA cycle), chemokine signaling pathway, B cell receptor signaling pathway. These pathways are involved in the regulation of multiple cellular functions and disease processes, highlighting the potential role of CCR1 in mediating these biological mechanisms.

[0077] Fig.26 The results showed that the expression of CD163 was associated with the following signaling pathways: vascular endothelial growth factor (VEGF) signaling pathway, tyrosine metabolism, taste transduction, starch and sucrose metabolism, sphingolipid metabolism, retinol metabolism, regulation of actin cytoskeleton, pentose and glucuronic acid interconversion, pathogenic Escherichia coli infection, olfactory transduction, O-glycosylation biosynthesis, cytochrome P450 of xenobiotic metabolism, leishmaniasis infection, chondroitin sulfate glycosaminoglycan biosynthesis, gap junction, Fcγ-mediated phagocytosis, FcεRI signaling pathway, drug metabolism: cytochrome P450, B cell receptor signaling pathway. As a potential regulator in these pathways, changes in the expression of CD163 may have a significant impact on these biological processes.

[0078] Fig. 27 The results showed that the expression of P2RY13 was associated with the following signaling pathways: vascular endothelial growth factor (VEGF) signaling pathway, taste transduction, steroid hormone biosynthesis, starch and sucrose metabolism, regulation of actin cytoskeleton, primary bile acid biosynthesis, porphyrin and chlorophyll metabolism, pentose and glucuronic acid interconversion, pathogenic Escherichia coli infection, mitosis-activated protein kinase (MAPK) signaling pathway, gonadotropin-releasing hormone (GnRH) signaling pathway, chondroitin sulfate glycosaminoglycan biosynthesis, fructose and mannose metabolism, drug metabolism: other enzymes, drug metabolism: cytochrome P450, cysteine ​​and methionine metabolism, bladder cancer, B cell receptor signaling pathway, autoimmune thyroid disease, ascorbic acid and aldonic acid metabolism. As a potential regulator in these pathways, P2RY13 may provide new strategies and targets for disease prevention and treatment.

[0079] Results of docking of active ingredients with protein molecules in TFDM: using SwissADME TMAnalysis platform and literature collection, this example identified the active ingredients in TFDM. In order to ensure the accuracy and completeness of the data, a few bioactive molecules were added as candidate active molecules based on literature reports, although they did not meet the screening criteria. Ultimately, 21 compounds were selected as candidate active molecules, and the results are shown in Table 1.

[0080] Table 1 21 compounds selected as candidate active molecules

[0081]

[0082]

[0083] The molecular docking results showed the binding ability and interaction of 21 active ingredients in TFDM with C1QTNF9, P2RY13, CD163, and CCR1. The results with higher binding ability were visualized, e.g. Figures 28 to 31 shown.

[0084] The present invention evaluates the differentially expressed genes (DEGs) between patients with ischemic heart failure and a normal control group, and explores key modules based on weighted gene co-expression network analysis (WGCNA). Characteristic genes associated with ischemic heart failure were identified by LAS SO and random forest analysis, including C1QTNF 9, CCR1, CD163 and P2RY13. Subsequently, gene set enrichment analysis (GSEA) was applied to study the signaling pathways associated with the central genes. Finally, the present invention further evaluates the interaction between the corresponding protein targets of these genes and the active ingredients in the total flavonoids extract of Scutellaria baicalensis. TFDM is a substance known in the art to have a pharmacological protective effect on myocardial ischemia-reperfusion injury and cerebral ischemia-reperfusion injury. Based on the above content, it is confirmed that the four characteristic genes described in the present invention provide a new perspective for the clinical diagnosis and treatment of ischemic heart failure.

[0085] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. The use of characteristic genes as targets in the preparation of reagents for diagnosing heart failure, characterized in that: The characteristic genes include one or more of C1QTNF9, CCR1, CD163 and P2RY13.

2. Use of a reagent for detecting the expression level of a characteristic gene in the preparation of a reagent for diagnosing heart failure, characterized in that: The characteristic genes include one or more of C1QTNF9, CCR1, CD163 and P2RY13.

3. The use according to claim 2, characterized in that: The expression of C1QTNF9 is upregulated, the expression of CCR1 is downregulated, the expression of CD163 is downregulated, and the expression of P2RY13 is upregulated.

4. The use of characteristic genes combined with the total flavonoids extract of Herba Cibotii in the preparation of a drug for diagnosing and / or preventing and treating heart failure, characterized in that: The characteristic genes include one or more of C1QTNF9, CCR1, CD163 and P2RY13.

5. The use according to any one of claims 1 to 4, characterized in that: The heart failure includes ischemic heart failure.

6. A kit, characterized in that: The kit comprises reagents for detecting the expression level of characteristic genes, and the characteristic genes comprise one or more of C1QTNF9, CCR1, CD163 and P2RY13.

7. A method for detecting heart failure for non-disease diagnosis purposes, characterized in that: The method comprises the following steps: detecting the expression levels of C1QTNF9, CCR1, CD163 and P2RY13 in the sample to be tested, and judging whether the sample to be tested is a heart failure sample according to the expression levels of C1QTNF9, CCR1, CD163 and P2RY13: When one or more of the following four items are met, the sample to be tested is a heart failure sample; 1) the expression of C1QTNF9 is upregulated; 2) down-regulation of the expression of CCR1; 3) the expression of CD163 is downregulated; 4) the expression of P2RY13 is upregulated; Except for satisfying one or more of the above four items, the sample to be tested is a non-heart failure sample.

8. The method according to claim 7, characterized in that The detecting the expression levels of C1QTNF9, CCR1, CD163 and P2RY13 in the sample to be tested includes: detecting the relative expression levels of C1QTNF9, CCR1, CD163 and P2RY13 in the sample to be tested relative to the healthy sample.

9. The method according to claim 7 or 8, characterized in that: The heart failure includes ischemic heart failure.

10. A diagnostic marker for heart failure, characterized in that: Including two or more of C1QTNF9, CCR1, CD163 and P2RY13 genes.